Companies · Pharmaceuticals

AyuVis Research, Inc.

FORT WORTH · Pharmaceuticals

Diligence memoA one-page analyst read on AyuVis Research, Inc. — recommendation, valuation, rhythm, risks.
$2.0M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 73%
Sector rank · raised
Seed
Latest stage · inferred · Fri Apr 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

AyuVis Research, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.50× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.2 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

AyuVis Research, Inc. is one of 1613 Pharmaceuticals companies tracked from FORT WORTH. By capital raised it ranks in the long tail (ahead of 28% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
17
Investors (latest)
2018
Year incorporated
2019-04-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2018-04-19 Raised $220K (real) Modeled valuation $10M (est)$220K$10MPre-Seed2018Seed · 2018-04-19 Raised $1.3M (real) Modeled valuation $49M (est)$1.3M$49MSeed2018Seed · 2019-04-19 Raised $745K (real) Modeled valuation $28M (est)$745K$28MSeed2019Pre-Seed · 2019-04-19 Raised $745K (real) Modeled valuation $35M (est)$745K$35MPre-Seed2019+$1.3M+$745K+$745KCumulative $3.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$220K · 2018
Seed$1.3M · 2018
Seed extension$745K · 2019
Bridge · Seed-stage$745K · 2019smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$28.3M
Base estimate est.
$563K
Conservative case
$222.4M
Upside case
$3.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $10.4M · 2018-04-192018Seed · modeled $49.5M · 2018-04-19Seed · modeled $28.3M · 2019-04-19Pre-Seed · modeled $35.2M · 2019-04-192019
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
7.2 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$2.0M/yr
Capital velocity
8.2 yr
On record since
2018
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.0M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.4× of median
This company$745K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$28.3M
Sector median$76.1M

Raised more than 28% of sector peers (real $). Modeled value above 33% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #39 of 49.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Wiesman Capital & Co., LLC · Seed Raised $4.0M · modeled $152.2M (est)Curzion Pharmaceuticals, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Providence Therapeutics Inc. · Seed Raised $8.1M · modeled $132.2M (est)EnBiotix, Inc. · Seed Raised $6.6M · modeled $131.8M (est)Metuchen Pharmaceuticals, LLC · Seed Raised $3.1M · modeled $119.2M (est)VasoRx, Inc. · Seed Raised $4.7M · modeled $117.9M (est)Amplicore Inc. · Seed Raised $2.8M · modeled $107.1M (est)Lamassu Pharma, LLC · Seed Raised $2.7M · modeled $101.5M (est)Apertor Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $95.3M (est)Elgia Therapeutics, Inc. · Seed Raised $2.3M · modeled $88.6M (est)Pharmapotheca A, LLC · Seed Raised $3.1M · modeled $87.3M (est)ImmunoRx Pharma, Inc. · Seed Raised $2.7M · modeled $82.2M (est)AyuVis Research, Inc. (this company) Raised $2.0M · modeled $28.3M (est)AyuVis Research, Inc.
CompanyStageRaised · realValue · estvs peer med.
Wiesman Capital & Co., LLCSeed$4.0M$152.2M2.67×
Curzion Pharmaceuticals, Inc.Seed$3.5M$133.1M2.33×
Providence Therapeutics Inc.Seed$8.1M$132.2M2.32×
EnBiotix, Inc.Seed$6.6M$131.8M2.31×
Metuchen Pharmaceuticals, LLCSeed$3.1M$119.2M2.09×
VasoRx, Inc.Seed$4.7M$117.9M2.07×
Amplicore Inc.Seed$2.8M$107.1M1.88×
Lamassu Pharma, LLCSeed$2.7M$101.5M1.78×
Apertor Pharmaceuticals, Inc.Seed$3.0M$95.3M1.67×
Elgia Therapeutics, Inc.Seed$2.3M$88.6M1.55×
Pharmapotheca A, LLCSeed$3.1M$87.3M1.53×
ImmunoRx Pharma, Inc.Seed$2.7M$82.2M1.44×
AyuVis Research, Inc. this companySeed$2.0M$28.3M0.50×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$220K2018-04-19$1.2M$10.4M90%
Seed$1.3M2018-04-19$6.5M$49.5M90%
Seed$745K2019-04-19$3.7M$28.3M90%
Pre-Seed$745K2019-04-19$4.1M$35.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$220K2018-04-19
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Seed$1.3M2018-04-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.9× larger than the prior — scaling up.
    • 26 investors on this round.
  3. Seed$745K2019-04-19
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  4. Pre-Seed$745K2019-04-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 17 investors on this round.
Intelligence
2019 ~Q3
Modeled next raise · ~4mo cadence
$745K
Modeled next size est.range $745K$1.2M
1.0×
Last step-up
$2.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Beamon Dennis Agarwal2019-04
Dwight M Horton2019-04
Gagan M Acharya2018-04
Russell M Bromley2019-04
Stella M Robertson2018-04
Suchismita Acharya2018-04
William Dennis Dean2019-04
Registry & provenance

AyuVis Research, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1739776
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Black Swan Pharmaceuticals, Inc.PharmaceuticalsSeed$2.0M$39.0Msame sector · same stage
Femmepharma Holding Co IncPharmaceuticalsSeed$2.0M$25.9Msame sector · same stage
S1P Therapeutics Inc.PharmaceuticalsSeed$2.0M$16.9Msame sector · same stage
Balto Pharmaceuticals, Inc.PharmaceuticalsSeed$2.0M$14.9Msame sector · same stage
CanaQuest Medical Corp.PharmaceuticalsSeed$2.0M$22.8Msame sector · same stage
LGM Holdings, LLCPharmaceuticalsSeed$2.0M$35.3Msame sector · same stage
Pierrepont Therapeutics, Inc.PharmaceuticalsSeed$2.1M$11.4Msame sector · same stage
Vitalis Therapeutics, Inc.PharmaceuticalsSeed$2.0M$20.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aya Biosciences, Inc.PharmaceuticalsSeries A$129.3M89%
Anivive Lifesciences, Inc.PharmaceuticalsSeries C$1.1B87%
Anebulo Pharmaceuticals, Inc.PharmaceuticalsSeries A$62.4M84%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M83%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B83%
Khloris Biosciences, Inc.PharmaceuticalsSeries A$154.9M82%
Ankyra Therapeutics, Inc.BiotechnologySeries C$1.2B82%
Pharmaceutics International, Inc.PharmaceuticalsSeries D+$124.0M82%
Frequently asked
How much funding has AyuVis Research, Inc. raised?
AyuVis Research, Inc. has raised approximately $2.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is AyuVis Research, Inc.'s estimated valuation?
Provath's modeled valuation for AyuVis Research, Inc. is approximately $28.3M (modeled range $563K–$222.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AyuVis Research, Inc. at?
AyuVis Research, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Apr 19.
What does AyuVis Research, Inc. do and where is it based?
AyuVis Research, Inc. operates in the Pharmaceuticals sector, based in FORT WORTH.
Explore related

See where AyuVis Research, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AyuVis Research, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.